Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: An image capturing apparatus includes: an image capturing unit; a focus detection unit that detects a focus position of an imaging optical system based on a phase-difference detection method; an imaging control unit that controls the image capturing unit to make the image capturing unit acquire pieces of light field data in one-to-one correspondence with a plurality of focus positions of the imaging optical system; and a generation unit that generates a refocused image corresponding to a focus position between the plurality of focus positions of the imaging optical system using the pieces of light field data, the generation depending on a direction of phase-difference detection by the focus detection unit and on a direction of parallax in the pieces of light field data.

Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: An image pickup apparatus includes a motor, a shutter charge mechanism which rotates the motor in a first direction to perform a charge operation of a shutter, a flash pop-up mechanism which rotates the motor in a second direction to move a flash to an up state, a state detector which detects the up state of the flash, a clutch mechanism which cuts off a transmission between the motor and the flash pop-up mechanism when the motor rotates in the first direction, and cuts off a transmission between the motor and the shutter charge mechanism when the motor rotates in the second direction, and a controller which controls the motor to rotate in the first direction to drive the shutter charge mechanism when the state detector detects the up state of the flash after the motor rotates in the second direction to drive the flash pop-up mechanism.

Abstract: Methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof and methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. Also, methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA with an effective amount of one or more adenosine A2A receptor antagonists, optionally with a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: An image pickup apparatus includes a motor, a shutter charge mechanism which rotates the motor in a first direction to perform a charge operation of a shutter, a flash pop-up mechanism which rotates the motor in a second direction to move a flash to an up state, a state detector which detects the up state of the flash, a clutch mechanism which cuts off a transmission between the motor and the flash pop-up mechanism when the motor rotates in the first direction, and cuts off a transmission between the motor and the shutter charge mechanism when the motor rotates in the second direction, and a controller which controls the motor to rotate in the first direction to drive the shutter charge mechanism when the state detector detects the up state of the flash after the motor rotates in the second direction to drive the flash pop-up mechanism.

Abstract: An image capturing apparatus includes an image sensor which photo-electrically converts an object image formed by an objective lens, a shutter which is arranged between the objective lens and the image sensor, opens to set the image sensor in an exposure enable state, and closes to set the image sensor in a light-shielding state, a dark image acquisition unit which acquires a dark image by closing the shutter and causing the image sensor to accumulate charges, and a control unit which controls an aperture size of an aperture stop arranged at the objective lens, wherein if the aperture stop has a aperture size more than a predetermined aperture size before acquiring the dark image, the dark image acquisition unit acquires the dark image after the control unit controls the aperture stop to an aperture size not more than the predetermined aperture size.

Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: A leather-like sheet excellent in stretchability which is obtained by integrating by entanglement of a woven or knitted fabric and an ultrafine fiber of 0.0001 to 0.5 dtex, wherein at least one face of the leather-like sheet is substantially composed of said ultrafine fibers, and said woven or knitted fabric consists of a conjugate fiber in which two or more kinds of polyester-based polymers, at least one of which consists essentially of polytrimethylene terephthalate, are stuck along the fiber length direction side-by-side, or a conjugate fiber in which two or more kinds of polyester-based polymers, at least one of which consists essentially of polytrimethylene terephthalate, forms an eccentric sheath-core type conjugate structure, and the fiber constituting the woven or knitted fabric has a twist coefficient of 20000 or below.

Abstract: A music tuner comprising a contact sensing device, a non-contact sensing device, or a combination of both, is integrated onto the body of an electric stringed music instrument. The present invention aims to make it more convenient for the user of the electric ukulele by eliminating the need to separately account for the music tuner and by preventing the music tuner from being misplaced or lost.

Abstract: An image capturing apparatus includes an image sensor which photo-electrically converts an object image formed by an objective lens, a shutter which is arranged between the objective lens and the image sensor, opens to set the image sensor in an exposure enable state, and closes to set the image sensor in a light-shielding state, a dark image acquisition unit which acquires a dark image by closing the shutter and causing the image sensor to accumulate charges, and a control unit which controls an aperture size of an aperture stop arranged at the objective lens, wherein if the aperture stop has a aperture size more than a predetermined aperture size before acquiring the dark image, the dark image acquisition unit acquires the dark image after the control unit controls the aperture stop to an aperture size not more than the predetermined aperture size.

Abstract: The present invention provides a therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia comprising, as an active ingredient, a tricyclic compound represented by formula (I): [wherein R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy or halogen; X1-X2-X3 represents CR5?CR6—CR7?CR8, N(O)m?CR6—CR7?CR8, CR5?CR6—N(O)m?CR8, CR5?CR6—CR7?N(O)m, CR5?CR6—O, CR5?CR6—S, O—CR7?CR8, S—CR7?CR8 or O—CR7?N; Y represents 13 CH2S—, —CH2SO—, —CH2SO2—, —CH2O—, —CH?CH—, —(CH2)p—, —SCH2—, —SOCH2—, —SO2CH2— or —OCH2—; and R2 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralky

Abstract: The present invention provides a therapeutic agent for overactive bladder comprising, as an active ingredient, a tricyclic compound represented by formula (I): [wherein R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X1—X2—X3 represents CR5?CR6—CR7?CR8, CR5?CR6—S, and the like; Y represents —CH2S—, —SOCH2—, and the like; and R2 represents a hydrogen atom, and the like] or a pharmaceutically acceptable salt thereof.

Abstract: A leather-like sheet excellent in stretchability which is obtained by integrating by entanglement of a woven or knitted fabric and an ultrafine fiber of 0.0001 to 0.5 dtex, wherein at least one face of the leather-like sheet is substantially composed of said ultrafine fibers, and said woven or knitted fabric consists of a conjugate fiber in which two or more kinds of polyester-based polymers, at least one of which consists essentially of polytrimethylene terephthalate, are stuck along the fiber length direction side-by-side, or a conjugate fiber in which two or more kinds of polyester-based polymers, at least one of which consists essentially of polytrimethylene terephthalate, forms an eccentric sheath-core type conjugate structure, and the fiber constituting the woven or knitted fabric has a twist coefficient of 20000 or below.

Abstract: The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K+ channel opening activity as an index.

Abstract: The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K+ channel opening activity as an index.

Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.